These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 15652317

  • 1. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederen E, Virgolini I, Poewe W, Wenning GK.
    Neuroimage; 2005 Feb 01; 24(3):822-31. PubMed ID: 15652317
    [Abstract] [Full Text] [Related]

  • 2. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
    Vermeulen RJ, Drukarch B, Verhoeff NP, Goosen C, Sahadat MC, Wolters EC, van Royen EA, Stoof JC.
    Synapse; 1994 Jun 01; 17(2):115-24. PubMed ID: 7916490
    [Abstract] [Full Text] [Related]

  • 3. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.
    J Cereb Blood Flow Metab; 2001 Jan 01; 21(1):92-7. PubMed ID: 11149673
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT.
    Scherfler C, Donnemiller E, Schocke M, Dierkes K, Decristoforo C, Oberladstätter M, Kolbitsch C, Zschiegner F, Riccabona G, Poewe W, Wenning G.
    Neuroimage; 2002 Sep 01; 17(1):128-41. PubMed ID: 12482072
    [Abstract] [Full Text] [Related]

  • 5. Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats.
    Crunelle CL, de Wit TC, de Bruin K, Ramakers RM, van der Have F, Beekman FJ, van den Brink W, Booij J.
    Nucl Med Biol; 2012 Jul 01; 39(5):640-4. PubMed ID: 22261145
    [Abstract] [Full Text] [Related]

  • 6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W, Grundmann M, Huber G.
    Radiologe; 1995 Nov 01; 35(11):838-43. PubMed ID: 8657887
    [Abstract] [Full Text] [Related]

  • 7. Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice.
    Meyer PT, Salber D, Schiefer J, Cremer M, Schaefer WM, Kosinski CM, Langen KJ.
    Nucl Med Biol; 2008 Jul 01; 35(5):543-8. PubMed ID: 18589298
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW.
    Eur J Nucl Med Mol Imaging; 2007 Apr 01; 34(4):502-7. PubMed ID: 17053905
    [Abstract] [Full Text] [Related]

  • 9. Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.
    Catafau AM, Bullich S, Danús M, Penengo MM, Cot A, Abanades S, Farré M, Pavía J, Ros D.
    Synapse; 2008 Jan 01; 62(1):62-9. PubMed ID: 17960766
    [Abstract] [Full Text] [Related]

  • 10. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Jan 01; 37(1):11-5. PubMed ID: 8543979
    [Abstract] [Full Text] [Related]

  • 11. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD, Abrams DN, Greenberg CR, Hobson D.
    J Nucl Med; 1996 Oct 01; 37(10):1589-91. PubMed ID: 8862288
    [Abstract] [Full Text] [Related]

  • 12. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
    Matsumura K, Toyama H, Nakashima H, Ichise M, Kurami M, Nakagawa T, Maeda H, Takeuchi A, Koga S.
    Kaku Igaku; 1994 May 01; 31(5):513-9. PubMed ID: 8028224
    [Abstract] [Full Text] [Related]

  • 13. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.
    Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van Heertum RL, Mann JJ, Laruelle M.
    Synapse; 1999 Mar 15; 31(4):302-8. PubMed ID: 10051112
    [Abstract] [Full Text] [Related]

  • 14. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC.
    J Nucl Med; 1993 Aug 15; 34(8):1274-81. PubMed ID: 8326384
    [Abstract] [Full Text] [Related]

  • 15. [123I]Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine--an in vivo imaging study with a dedicated small animal SPECT.
    Nikolaus S, Larisch R, Wirrwar A, Jamdjeu-Nouné M, Antke C, Beu M, Schramm N, Müller HW.
    Eur J Nucl Med Mol Imaging; 2005 Nov 15; 32(11):1305-10. PubMed ID: 16003562
    [Abstract] [Full Text] [Related]

  • 16. Small animal imaging using a conventional gamma camera exemplified in studies on the striatal dopaminergic system.
    Scherfler C, Decristoforo C.
    Nucl Med Rev Cent East Eur; 2006 Nov 15; 9(1):6-11. PubMed ID: 16791797
    [Abstract] [Full Text] [Related]

  • 17. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M, Henkes H, Laudahn D, Bräu H, Kramp W, Girke W, Hierholzer J, Eichstädt H, Felix R.
    Eur J Radiol; 1991 Nov 15; 12(3):182-6. PubMed ID: 1830273
    [Abstract] [Full Text] [Related]

  • 18. Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach.
    Meyer PT, Sattler B, Winz OH, Fundke R, Oehlwein C, Kendziorra K, Hesse S, Schaefer WM, Sabri O.
    Neuroimage; 2008 Aug 15; 42(2):548-58. PubMed ID: 18595739
    [Abstract] [Full Text] [Related]

  • 19. A single-scan protocol for absolute D2/3 receptor quantification with [123I]IBZM SPECT.
    Tsartsalis S, Tournier BB, Aoun K, Habiby S, Pandolfo D, Dimiziani A, Ginovart N, Millet P.
    Neuroimage; 2017 Feb 15; 147():461-472. PubMed ID: 28011253
    [Abstract] [Full Text] [Related]

  • 20. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E, Verhoeff NF, Speelman JD, Wolters EC, Kuiper MA, Janssen AG.
    Arch Neurol; 1993 May 15; 50(5):513-6. PubMed ID: 8489409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.